antigen

(redirected from HBeAg)
Also found in: Thesaurus, Medical, Acronyms, Encyclopedia.
Related to HBeAg: anti-HBe, HBeAb, HBcAg

an·ti·gen

 (ăn′tĭ-jən) also an·ti·gene (-jēn′)
n.
A molecule that is capable of binding to an antibody or to an antigen receptor on a T cell, especially one that induces an immune response. An antigen is usually a foreign substance, such as a toxin or a component of a virus, bacterium, or parasite.

an′ti·gen′ic (-jĕn′ĭk) adj.
an′ti·gen′i·cal·ly adv.
an′ti·ge·nic′i·ty (-jə-nĭs′ĭ-tē) n.

antigen

(ˈæntɪdʒən; -ˌdʒɛn) or

antigene

n
(Biochemistry) a substance that stimulates the production of antibodies
[C20: from anti(body) + -gen]
ˌantiˈgenic adj
ˌantiˈgenically adv

an•ti•gen

(ˈæn tɪ dʒən, -ˌdʒɛn)

n.
1. any substance that can stimulate the production of antibodies and combine specifically with them.
2. any commercial substance that, when injected or absorbed into animal tissues, stimulates the production of antibodies.
3. antigens of a particular type collectively.
[1905–10; anti (body) + -gen]
an`ti•gen′ic, adj.
an`ti•gen′i•cal•ly, adv.
an`ti•ge•nic′i•ty (-dʒəˈnɪs ɪ ti) n.

an·ti·gen

(ăn′tĭ-jən)
A substance that stimulates the production of an antibody when introduced into the body. Antigens include toxins, bacteria, viruses, and other foreign substances. See Note at blood type.

antigen

A molecule recognized as foreign by the body’s immune system, causing the release of antibodies.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.antigen - any substance (as a toxin or enzyme) that stimulates an immune response in the body (especially the production of antibodies)
substance - a particular kind or species of matter with uniform properties; "shigella is one of the most toxic substances known to man"
immunizing agent, immunogen - any substance or organism that provokes an immune response (produces immunity) when introduced into the body
immunology - the branch of medical science that studies the body's immune system
agglutinogen - any substance that acts as an antigen to cause agglutinin production
fetoprotein, foetoprotein - any of several antigens that occur naturally in the fetus and sometimes in adults with cancer
anatoxin, toxoid - a bacterial toxin that has been weakened until it is no longer toxic but is strong enough to induce the formation of antibodies and immunity to the specific disease caused by the toxin; "diphtheria toxoid"
antigenic determinant, epitope, determinant - the site on the surface of an antigen molecule to which an antibody attaches itself
Rh, Rh factor, rhesus factor - a blood group antigen possessed by Rh-positive people; if an Rh-negative person receives a blood transfusion from an Rh-positive person it can result in hemolysis and anemia
Translations
antigen
antigeeni
antigén
antígeno
antigen
antigen

antigen

[ˈæntɪdʒən] Nantígeno m

antigen

[ˈæntɪdʒən] nantigène manti-hero antihero [ˈæntihɪərəʊ] nantihéros m

antigen

nAntigen nt

antigen

[ˈæntɪdʒən] nantigene m

an·ti·gen

n. antígeno, sustancia tóxica que estimula la formación de anticuerpos;
carcinoembriogenic ______ carcinoembriogénico.

antigen

n antígeno; carcinoembryonic — antígeno carcinoembrionario; prostate-specific — (PSA) antígeno prostático específico (APE)
References in periodicals archive ?
CRV431 has demonstrated an ability to reduce multiple markers of HBV infection including reductions in DNA, HBsAg, HBeAg, and HBV uptake by liver cells.
Moreover, HBeAg induced the expansion of MDSCs through the upregulation of a molecule called indoleamine-2, 3-dioxygenase (IDO), which plays a critical role in the suppression of T-cell proliferation.
NA'larin kesilmesinde belirtec olarak rolu tam olarak bilinmemektedir; ancak bazal anti-HBc seviyesinin, Peg-IFN-[alpha] veya NA tedavileri sirasinda HBeAg serokonversiyonunda guclu bir on belirtec oldugu vurgulanmistir (8).
Baseline biochemical parameters (AST, 0-35 U/L; ALT, 0-35 U/L), serological markers (HBeAg, antiHBe, HBsAg, and antiHBS), viral loads (HBV DNA, IU/mL), complete blood counts, prior liver biopsies, ongoing treatments, and treatment durations were recorded as pre-treatment values.
Firstly, at the transcriptional level, the BCP mutations 1762T 1764A have an affect on the transcription of the precore mRNA, which results in the reduction of HBeAg expression.
Yet, in chronic HBV infection, HBV, HBeAg, and HBV surface antigen (HBsAg) can impair the mature and function of DCs.[10],[11],[12] However, it is not fully understood what cytokines involve in triggering the immune response against HBV during IT phase transition to immune clearance phase, and why chronic hepatitis B (CHB) patients with higher ALT level could obtain more HBeAg seroconversion after pegylated (PEG)-IFN a2 therapy.
The WHO, AASLD, APASL, and EASL guidelines recommend the monitoring of HBeAg status, HBV DNA level, and ALT level for detection of HBV infection phase.
Studies from Asia report that the rate of spontaneous HBeAg seroconversion is higher in HBV genotype B-infected persons compared to those infected with genotype C (40-42).
Patient data collected retrospectively from medical records for description as well as comparison between VCTE-classified groups of severities of liver fibrosis were patient demographics and baseline characteristics including body mass index (BMI), serum albumin (g/dL), total bilirubin (mg/dL), serum creatinine (mg/dL), HBeAg serostatus, HBV DNA level (IU/mL), aspartate transaminase (AST) level (U/L), alanine transaminase (ALT) level (U/L), alkaline phosphatase (ALP) level (U/L), international normalized ratio (INR), white blood cell count (WBC) (/mm3), hemoglobin (g/dL), and platelet (x109/L).
In endemic areas, where carrier rates are greater than 5%, perinatal transmission is common, especially when HBV-infected mothers are also HBeAg positive [5, 6].